Background: We conducted a meta-analysis of articles published between January 2000 and July 2016 with the aim of defining the proportion of rubella seronegative women of childbearing age (WCBA), providing the best information available on the seroprevalence of rubella in this population. Methods: We selected articles published in the time period between 2000 and 2016. The pooled prevalence of rubella seronegative women was calculated by a fixed effect model and a random effect model, according to the heterogeneity among studies. Studies were subgrouped by population type (pregnant women and WCBA with no mention of ongoing pregnancy) and by geographic area [World Health Organization (WHO) region]. Sensitivity analysis was performed to assess the stability of results. Results: We found important differences in rubella seronegativity prevalence estimates by WHO Region. About 88% of the studies conducted on pregnant women reported a seronegativity rate >5%. The pooled rubella seronegativity prevalence was 9.3%. When considering population groups, we obtained a seronegativity pooled estimate of 9.4% for pregnant women and of 9.5% for WCBA with no mention of ongoing pregnancy. Conclusions: This meta-analysis shows that the proportion of WCBA who are susceptible to rubella is still high. The figures are worrisome, taking into account that the WHO set at 5% the rubella susceptibility threshold for WCBA. 
Background

T
he World Health Organization (WHO) aims at eliminating rubella and at preventing congenital rubella syndrome (CRS) in at least 5 WHO Regions by 2020. 1 In Europe, a rubella (including CRS) elimination strategy was launched in 2012, 2 based on the experiences of the WHO regions and countries that successfully eliminated the indigenous transmission of this disease. A combined vaccination strategy with a universal approach (two doses of a rubella-containing vaccine in children aged 1-6 years and one dose in susceptible adults through a catch-up campaign), contributed to the elimination of rubella in the Americas, as observed in US Costa Rica and in Mexico. 3, 4 The main goal of an effective immunization strategy is achieving and maintaining high levels of population immunity. Suboptimal coverage levels in childhood (<95%) can lead to a prolonged inter-epidemic period and to a paradoxical shift of the disease incidence towards older age groups, including women of childbearing age (WCBA), with a consequent increase of CRS, 5 as already reported in Europe. 6, 7 According to the WHO global estimates, in 2008, infants born with CRS exceeded 110 000, with the highest CRS burden in SouthEast Asia ($48%) and African ($38%) Regions.
With the aim of describing the seroprevalence of rubella in WCBA and pregnant women at a global level, we conducted a meta-analysis of articles published between January 2000 and July 2016 reporting data on rubella seronegativity among WCBA or pregnant women.
Methods
Search methods and study selection
A literature search on the prevalence of rubella-seronegative WCBA was performed on the databases reported in table 1. We crossed the words (rubella OR TORCH) AND (immunity OR seronegative OR susceptibility OR seroprevalence OR sero-prevalence OR seroepidemiology OR sero-epidemiology OR serology OR seroprofile OR antibodÃ) AND (pregnanÃ OR childbearing OR women OR antenatal). We selected articles in English language published in the time period between 1 January 2000 and 31 July 2016. We examined the references of all articles for additional studies.
Of each article included in the review, the following epidemiological data were recorded: study site (WHO region, Country, State, region, city); main study characteristics (study year, population or individuals included in the study, population sampling), total number of seronegative individuals (as calculated in each study based on the reported cut-off).
We contacted the authors of the selected articles to validate and correct, if needed, data extracted from the published studies.
We excluded articles that analysed local data when nationwide studies were available from the literature, articles that did not report information on the studied population, those that were not available in English language or in full text and those reporting data for highly selected populations (e.g. HIV positive individuals or communities of immigrants).
Articles based on a population that was not exclusively composed of WCBA or pregnant women were included only if specific data regarding the subgroup of WCBA or pregnant women were reported.
Ethical approval
The study was approved by the Bambino Gesù Children's Hospital's ethical committee.
Statistical analysis
The prevalence of rubella seronegative women of each study was calculated by dividing the number of seronegative cases by the study population.
The pooled prevalence of rubella seronegative women was calculated by a fixed effect model, using the Mantel-Haenszel method, and a random effect model, using the DerSimonian-Laird method, according to the heterogeneity among studies.
To evaluate heterogeneity between studies I 2 statistic and Cochran's X 2 test was calculated. We performed the analysis for WCBA with any characteristic. We also sub-grouped data by type of population (pregnant women or WCBA with no mention of ongoing pregnancy) and by geographic area (WHO region).
Sensitivity analysis was performed by sequentially excluding individual studies to assess the stability of the results. For all analyses, the overall effect size (ES) was evaluated by Z test.
Statistical analyses were performed using the STATA 11.2 software. The P values < 0.05 was considered to be statistically significant.
Results
Selected articles
The search strategy identified a total of 307 studies, including related articles identified through the reference lists of the selected articles. A total of 201 articles were excluded, as they were not available in full text or in English language, did not report data on the study population, were based on a highly selected population or reported local data when nationwide studies were available. A resulting group of 106 articles were included in the review (figure 1). As the study by Nardone published in 2008 13 reported specific data from 17 different European countries, each population was considered as a separate study. Therefore, we included in the review a total of 122 study populations. All studies were included in the meta-analysis. [13] [14] [15] [16] [17] [18] [19] 
Study characteristics
Characteristics of the 122 study populations (WHO region, population size and type, country and seronegativity prevalence) are reported in table 2. Among the selected studies, 41% were conducted in the European Region (EUR), 13% in the American Region (AMR), 12% in the Middle East Region (EMR), 16% in the Africa Region (AFR), 8% in the South East Asian Region (SEAR) and 10% in the Western Pacific Region (WPR). Of the selected studies, 41% were based on a population of WCBA with no mention of ongoing pregnancy and 59% on a population of pregnant women (table 2) . In the articles included in the analysis, we observed a seronegativity prevalence ranging from a minimum of 0% to a maximum of 53%, with a median of 7.5%.
A total of 18 studies (15%) reported a seronegativity prevalence <5%, 55 studies (45%) reported a seronegativity prevalence ranging from 5 to 10%, and 49 studies (40%) reported a seronegativity prevalence higher than 10%. Nearly 40% of the studies conducted on pregnant women reported a figure >10%, and almost 50% reported a figure between 5 and 10%. Forty-two percent of the studies conducted on WCBA reported a figure >10%, while 40% reported a figure between 5 and 10%. Thirteen percent of the studies conducted on pregnant and 18% conducted on WCBA reported a figure <5% (table 3) .
Sixteen studies (32%) from EUR, all studies from SEAR (20%) and 7 studies (14%) from AMR reported a seronegativity rate >10%. Only very few studies documented a seronegativity rate <5%, in line with the WHO goal, except EUR region with 56%.
Pooled rubella seronegativity prevalence
Using the fixed effect method, we obtained a pooled rubella seronegativity prevalence estimate of 4.3% (95%CI: 4.29-4.35), test for overall ES Z = 270.5 (P < 0.0001), with a high heterogeneity in the selected studies (I 2 = 99.7%; P < 0.0001). Using the random effect method, we obtained a pooled rubella seronegativity prevalence estimate of 9.3% (95%CI: 8.7-10.0), test for overall ES Z = 27.19 (P < 0.0001). There was a significant heterogeneity among estimates between the 122 studies (I 2 = 99.7%; P < 0.0001).
When sub-grouping selected articles by WHO Region, we found important differences in rubella seronegativity prevalence estimates. Nineteen studies provided data for AFR producing a pooled estimate of 10.7% (95%CI: 8.6-12.9), 16 studies provided data for AMR and the pooled rubella seronegativity prevalence estimate was 9.7% (95%CI: 6.9-12.5), 15 studies provided data for EMR with an estimate of 6.9% (95%CI: 5.2-8.6), 50 studies provided data for EUR with an estimate of 7.6% (95%CI: 6.8-8.3), 10 studies provided data for SEAR with an estimate of 19.4% (95%CI: 13.3-25.4), and 12 studies provided data for WPR with an estimate of 9.0% (95%CI: 6.7-11.3). The highest heterogeneity was reported in AMR (I 2 = 99.9%; P < 0.0001), WPR (I 2 = 99.7%; P < 0.0001) and EUR (I 2 = 98.9%; P < 0.0001) (figure 2). When considering population groups, we obtained a seronegativity pooled estimate of 9.4% (95%CI: 8.5-10.2) for pregnant women and of 9.5% (95%CI: 8.1-10.8) for WCBA. The highest heterogeneity was reported in pregnant women (I 2 = 99.8%; P < 0.0001); WCBA (I 2 = 96.9%; P < 0.0001).
The sensitivity analysis did not show a high level of heterogeneity between studies, thus no study was excluded from the analysis.
Discussion
With the present meta-analysis, we show that, at a global level, the proportion of WCBA susceptible to rubella is still high.
We identified a pooled prevalence of rubella of 9.3%; 9.5% among WCBA with no mention of pregnancy and of 9.4% among pregnant women. These figures are worrisome, taking into account that the WHO set at 5% the rubella susceptibility threshold for WCBA. 2 Specifically, the limit set by the WHO was exceeded in 85% of the studies included in our meta-analysis.
As a matter of fact, it is difficult to compare seroprevalence figures among countries, because different serological methods and assays for rubella diagnosis are used worldwide, and the interpretation of the serological results may vary depending on the immunoassays. 20, 21 To reduce this gap, in 1996, the European SeroEpidemiology Network (ESEN) was established, with the aim of standardizing serological surveillance, ensuring the comparability of laboratory results of vaccine preventable diseases. 22, 23 In 2001, ESEN2 extended this network to include 17 countries (16 countries from the WHO European Region and Australia). 24 Seronegativity rates were heterogeneous among WHO regions. This is probably due to the differences in immunization strategies among countries. The highest seronegativity rate (19.4%) was recorded in the SEAR, followed by AFR (10.7%) and AMR (9.7%).
Prevention strategies were different among countries: although a proved, highly effective strategy is the adult mass vaccination targeting both men and women, 8 some countries adopted a selective vaccination programme for adolescent females, to prevent infection in pregnant women. Seventy-two (59%) articles reported specific data on pregnant women, more than a third of which reported a seronegativity prevalence >10%. Most of the countries which reported a high seronegativity rate among pregnant women had a rubella vaccination strategy in place, mainly adopting a universal approach, while others had a selective strategy for post-partum women or catch-up programmes for adolescents. No substantial differences in rubella seronegativity prevalence seem to be linked to vaccination strategies in these countries. Moreover, in the reviewed studies, some countries (Ghana, Mozambique, Saudi Arabia, Sudan, India) did not use a rubella-containing vaccine until 2011.
The WHO Regional Committee for Europe set 2010 as the target date for the elimination of rubella and for prevention of congenital rubella infections in the WHO European Region, by achieving and maintaining a high vaccination coverage with two doses of rubellacontaining vaccine (!95%) and targeting susceptible populations, including WCBA.
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Calimeri (2012) Makhseed (2001) Lin (2015) Doroudchi (2002) Nardone (2008) Disinor (2004) Nardone (2008) Boonruang (2005) González-Escalada (2013) McElroy ( Nardone (2008) Demirdal (2009) Nardone (2008) Singla (2004) Reiche (2000) Subtotal ( Nardone (2008) Lawn (2000) Baka (2006) Hanaoka (2013) Ghafourian ( Russian Federation with 146.220 cases in 2004. 29, 30 In line with WHO estimates, our meta-analysis shows a high prevalence of rubella seronegativity in these countries in the same period. Namely, Romania and Poland had a seronegativity rate >10% in WCBA. In other European countries, seronegativity rates ranged from 1.4% in the Czech Republic to 45% in Turkey.
Two According to the European Surveillance Network, a total of 211 cases of rubella among pregnant women were reported for 2000-07. These were reported from six countries, namely France, UK, Italy, Switzerland, Norway, Spain and Sweden. 29 The higher incidence of rubella in pregnant women in these countries compared with those with a higher overall incidence may be explained by a higher notification rate.
Data regarding these countries show a variable seronegativity rate, >5% for France, Italy and Norway, while a seronegativity <5% was reported in 1 out of 2 studies set in UK, in 1 out of 3 studies set in Spain and in one Swedish study. The incidence of rubella in pregnant women and the fact that most studies from these countries reported a seronegativity >5% could be explained by a low coverage rate before 2011. 29 According to WHO estimates, the AFR region reported the higher prevalence of CRS, with 136 CRS cases and more than 2.000 rubella cases in 2006. 30 In our meta-analysis, studies from the AFR region showed different seronegativity rates ranging from 4.9% of Sudan to 52% of Senegal (data for pregnant women). In AFR, indeed, no rubella vaccination strategy was in place until 2013, and Rwanda was the first country to launch a rubella campaign with Global Vaccine Alliance (GAVI) support in March 2013. 31 AMR region set the target of rubella elimination in 2000. 4 Between 2000 and 2016, in most AMR region the prevalence was higher than the threshold fixed by the WHO: most of the included studies set in AMR reported data on pregnant women, with seronegativity rates almost steadily over 5%. Interestingly, the highest and the lowest seronegativity in AMR studies were seen in Brazil. The first study 32 was set in 2007 and reported a seronegative rate of 28%. The second study, 33 published in 2016 and reporting data collected in 2012, showed a seronegativity rate of 2.8%. Interestingly, data from the second study were collected after a rubella immunization campaign which was held in 2008.
A notable exception in the AMR region is represented by the US. The US documented elimination of rubella reporting the absence of endemic rubella viruses from 2004 to 2007. 34, 35 The last endemic rubella and CRS cases were registered in 2009, and rubella cases reported until 2011 were from imported genotypes. 4, 35 The US experience shows that rubella elimination is possible investing not only in vaccination strategies but also in vaccination campaigns and surveillance at a national level to timely detect endemic transmission. 4 To ensure high vaccination coverage (>90%) in adolescents and adults, the US federal government spends 4 billion dollars annually; in 2010 also adolescent coverage was higher than 90%.
In a recent paper, a mathematical model was used to estimate CRS incidence from seroprevalence studies in two periods, 1996 and 2000-10 (i.e. before after introduction of rubella vaccine), and a persistence of a high CRS incidence was shown in all regions except AMR, EUR and EMR. 36 This article reported the highest estimated incidence in SEAR and AFR, accordingly to our results showing the highest seronegativity rates in these two regions, in which most countries have not yet adopted a rubella vaccination strategy.
This meta-analysis has several limitations. The main limitation is that we observed a significant heterogeneity regarding rubella seronegativity rate among the included studies. This heterogeneity may be due to differences in study populations, age groups and geographical areas. In addition, included studies were set in countries with different vaccination strategies and different notification systems. Moreover, included studies were published during a large time span (16 years), during which substantial changes may have taken place.
However, data were analysed through a sensitivity analysis and this did not significantly reduce the heterogeneity within studies. In fact, after excluding articles with a higher heterogeneity, pooled prevalence estimates did not change significantly.
In order to obtain more accurate estimates of the disease burden, and ultimately to achieve rubella elimination, an enhanced rubella surveillance is crucial. For effective surveillance of CRS, active case finding with a multidisciplinary approach, involving the participation of obstetricians, neonatologists, pediatricians, ophthalmologists, cardiologists, audiologists, infectious disease specialists, virologists and epidemiologists would be desirable.
Serological surveillance is an important tool for the evaluation of vaccination programmes and avoids the limitations of passive disease reporting systems; this is one of the entry points for CRS surveillance, whose gaps limit the ability to monitor progress towards its elimination.
Achievement of the rubella elimination goal will require an increased awareness and commitment by decision makers and public health authorities in all European countries, in order to strengthen the MMR vaccination programmes and to implement surveillance, in line with the WHO guidelines for rubella and CRS.
